Faron wins regulator nod for €40m rights issue to fund immunotherapy pipeline

Faron Pharmaceuticals Oy ( (GB:FARN) ) has issued an update.

Faron Pharmaceuticals has received approval from the Finnish Financial Supervisory Authority for the Finnish-language prospectus related to its fully committed approximately EUR 40 million rights offering. The capital raise, targeting the issuance of up to 80 million new shares and additional treasury shares with freely tradable subscription rights in Helsinki and London, is expected to strengthen the company’s funding base as it advances its immunotherapy development pipeline, including the bexmarilimab program.

The subscription periods for shares and depository interests will run between 17 March and early April 2026, with Stifel Europe Securities acting as sole global coordinator and bookrunner and several international law firms advising on the transaction. Faron will also host Finnish- and English-language webcasts to brief investors on its development plans and the strategic rationale behind the offering, underlining the importance of this financing step for ongoing clinical work and its positioning in the immuno-oncology field.

More about Faron Pharmaceuticals Oy

Faron Pharmaceuticals is a Finland-based biopharmaceutical company listed on AIM in London and Nasdaq First North Growth Market Finland. The company focuses on developing immuno-oncology therapies, including its wholly owned investigational drug bexmarilimab, an immunotherapy targeting myeloid cell function to enhance anti-cancer immune responses in aggressive hematological malignancies such as AML and MDS.

For a thorough assessment of FARN stock, go to TipRanks’ Stock Analysis page.